Immatics (IMTX) Net Cash Flow (2019 - 2025)
Immatics recorded quarterly Net Cash Flow of $13.9 million in Q4 2025, down 84.57% quarter-over-quarter from $90.3 million in Q3 2025, and down 67.8% year-over-year from $43.3 million in Q4 2024.
Immatics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $13.9 million for Q4 2025.
- In Q4 2025, Net Cash Flow fell 67.8% year-over-year to $13.9 million; the TTM figure through Dec 2025 stood at $144.4 million (up 1437.13% YoY), while the FY2025 annual figure was $141.8 million, up 1332.01% from the prior year.
- Net Cash Flow came in at $13.9 million for Q4 2025 at Immatics, down from $90.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $148.3 million in Q4 2023 to a low of -$108.4 million in Q1 2024.
- A 5-year average of $8.2 million and a median of $11.5 million in 2022 frame the typical range for Net Cash Flow.
- Across the five-year window, Net Cash Flow sank 1905.08% in 2022 and surged 999.38% in 2023, its largest moves.
- Immatics' Net Cash Flow stood at -$31.7 million in 2021, then surged by 47.92% to -$16.5 million in 2022, then surged by 999.38% to $148.3 million in 2023, then sank by 70.84% to $43.3 million in 2024, then sank by 67.8% to $13.9 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $13.9 million, $90.3 million, and $27.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | 13.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.93 Mn |
| Dec 31, 2025 | 13.93 Mn |
| Sep 30, 2025 | 90.27 Mn |
| Sep 30, 2025 | 90.27 Mn |
| Jun 30, 2025 | 27.69 Mn |
| Jun 30, 2025 | 27.69 Mn |
| Mar 31, 2025 | 12.48 Mn |
| Mar 31, 2025 | 12.48 Mn |
| Dec 31, 2024 | 43.25 Mn |
| Dec 31, 2024 | 43.25 Mn |
| Sep 30, 2024 | 35.73 Mn |
| Sep 30, 2024 | 35.73 Mn |
| Jun 30, 2024 | 38.81 Mn |
| Jun 30, 2024 | 38.81 Mn |
| Mar 31, 2024 | -108.40 Mn |
| Mar 31, 2024 | -108.40 Mn |
| Dec 31, 2023 | 148.31 Mn |
| Dec 31, 2023 | 148.31 Mn |
| Sep 30, 2023 | -55.73 Mn |
| Sep 30, 2023 | -55.73 Mn |
| Jun 30, 2023 | 14.16 Mn |
| Jun 30, 2023 | 14.16 Mn |
| Mar 31, 2023 | -30.38 Mn |
| Mar 31, 2023 | -30.38 Mn |
| Dec 31, 2022 | -16.49 Mn |
| Dec 31, 2022 | -16.49 Mn |
| Sep 30, 2022 | -93.00 Mn |
| Sep 30, 2022 | -93.00 Mn |
| Jun 30, 2022 | 10.58 Mn |
| Jun 30, 2022 | 10.58 Mn |
| Mar 31, 2022 | 126.30 Mn |
| Mar 31, 2022 | 126.30 Mn |
| Dec 31, 2021 | -31.66 Mn |
| Dec 31, 2021 | -31.66 Mn |
| Sep 30, 2021 | -4.64 Mn |
| Sep 30, 2021 | -4.64 Mn |
| Jun 30, 2021 | -40.56 Mn |
| Jun 30, 2021 | -40.56 Mn |
| Mar 31, 2021 | -17.59 Mn |
| Mar 31, 2021 | -17.59 Mn |
| Dec 31, 2020 | -25.14 Mn |
| Dec 31, 2020 | -25.14 Mn |
| Sep 30, 2020 | 174.92 Mn |
| Sep 30, 2020 | 174.92 Mn |
| Jun 30, 2020 | 15.26 Mn |
| Jun 30, 2020 | 15.26 Mn |
| Mar 31, 2020 | -34.54 Mn |
| Mar 31, 2020 | -34.54 Mn |
| Dec 31, 2019 | 12.55 Mn |
| Dec 31, 2019 | 12.55 Mn |
| Sep 30, 2019 | 66.40 Mn |
| Sep 30, 2019 | 66.40 Mn |